EPS for Enzo Biochem, Inc. (ENZ) Expected At $-0.01

February 19, 2018 - By Vivian Park

 EPS for Enzo Biochem, Inc. (ENZ) Expected At $ 0.01
Investors sentiment decreased to 1.24 in Q3 2017. Its down 0.35, from 1.59 in 2017Q2. It fall, as 18 investors sold Enzo Biochem, Inc. shares while 28 reduced holdings. 23 funds opened positions while 34 raised stakes. 25.84 million shares or 2.45% more from 25.22 million shares in 2017Q2 were reported.
Panagora Asset Inc holds 0.02% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 533,144 shares. Bancorporation Of Montreal Can owns 12,738 shares or 0% of their US portfolio. Guggenheim Limited Liability Corporation has 13,331 shares. American Century Cos Incorporated has 47,329 shares for 0% of their portfolio. Credit Suisse Ag holds 31,942 shares or 0% of its portfolio. Millennium Mgmt Llc owns 188,199 shares. Raymond James Trust Na, a Florida-based fund reported 30,000 shares. 2.14 million were reported by Renaissance Ltd. California State Teachers Retirement Systems holds 0% or 65,508 shares. Tiaa Cref Management Ltd Liability stated it has 735,555 shares. Indexiq Advisors Limited Co holds 0.05% or 103,551 shares. Neuberger Berman Grp Inc Limited Liability stated it has 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). The New York-based Goldman Sachs Gru Inc has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Arizona-based Tci Wealth Advisors Incorporated has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Clarivest Asset Management Ltd reported 414,898 shares or 0.1% of all its holdings.

Since October 25, 2017, it had 0 insider purchases, and 5 selling transactions for $1.71 million activity. The insider WEINER BARRY W sold $547,214. Shares for $108,500 were sold by RABBANI ELAZAR on Wednesday, January 17.

Analysts expect Enzo Biochem, Inc. (NYSE:ENZ) to report $-0.01 EPS on March, 12.They anticipate $0.01 EPS change or 50.00 % from last quarter’s $-0.02 EPS. After having $-0.01 EPS previously, Enzo Biochem, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 1.29% or $0.09 during the last trading session, reaching $6.89. About 70,216 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since February 19, 2017 and is uptrending. It has outperformed by 27.62% the S&P500.

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company has market cap of $323.32 million. The firm operates in three divisions: Clinical Labs, Life Sciences, and Therapeutics. It currently has negative earnings. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition.

More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Seekingalpha.com which released: “Enzo Biochem (ENZ) on Q4 2017 Results – Earnings Call Transcript” on September 28, 2017, also Businesswire.com with their article: “Enzo Biochem Announces New Validated Cost-Effective Cervical Cancer Biomarker …” published on January 22, 2018, Businesswire.com published: “Enzo Biochem Announces NYS Department of Health’s Approval of a New Women’s …” on October 23, 2017. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Seekingalpha.com and their article: “Enzo Biochem Rounds The Corner” published on July 10, 2017 as well as Businesswire.com‘s news article titled: “Enzo Biochem Reports Delaware Court Ruling” with publication date: June 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.